Abstract library

176 results for "NETest".
#2836 Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience
Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Anna Malczewska
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1489 The Clinical Utility of Blood Neuroendocrine Gene Transcript Analysis, the NETest, in Paragangliomas and Pheochromocytomas
Introduction: Diagnosis of disease and identification of progression are critical issues in paraganglioma (PGL) and pheochromocytoma (PCC) management. An accurate blood biomarker that defines tumor biology irrespective of biochemical activity is lacking.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, PCR
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Francesca Muffatti
#2273 The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Follow-up after resection of pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence early, as incidence is reported up to 48%.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: M.D. Cansu Genc
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR